StreetAlpha.app
Home › Stocks › JAZZ

Jazz Pharmaceuticals plc (JAZZ)

Healthcare
$230.26
▼ −2.62%
LAST CLOSE · NOV 20

Jazz Pharmaceuticals develops and sells medicines for rare diseases, including sleep disorders, epilepsy and cancer. It last closed at $230.26 on Nov 20, down 2.62% on the day. The next earnings report for JAZZ is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, JAZZ reported EPS of -$7.48 on revenue of $1.24B, with revenue up 10.4% from a year ago. Over its last 8 reports the stock moved an average of 5.6% the session after earnings. Over the last 12 months JAZZ insiders bought $0 of stock on the open market and sold $81.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is JAZZ in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold JAZZ.

Key Stats

Last 12 months
Results
Revenue
$4.7B
+13.5% vs a year ago
Net income
$206.0M
4.4% margin
EPS (diluted)
$3.38
Free cash flow
$1.6B
34.4% margin
Valuation
Market cap
$14.8B
64.2M shares
P/E
68.1
Price over 12 month EPS
Price to sales
3.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.0B
At Sep 30
Debt
$5.6B
At Sep 30
Shareholder equity
$4.2B
Buybacks
$225.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.1B$3.1BFY2021FY2022: $3.7B$3.7BFY2022FY2023: $3.8B$3.8BFY2023FY2024: $4.1B$4.1BFY2024FY2025: $4.3B$4.3BFY2025

From JAZZ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$7.48
Quarter ended Sep 2026
Year ago EPS
$4.08
−283.3% on a GAAP basis
Revenue
$1.24B
+10.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $3.02Dec '24Mar 2025: -$1.52Mar '25Jun 2025: -$11.74Jun '25Sep 2025: $4.08Sep '25Dec 2025: $3.34Dec '25Mar 2026: $4.43Mar '26Jun 2026: $2.78Jun '26Sep 2026: -$7.48Sep '26Latest -$7.48
Revenue by quarter
Dec 2024: $1.09BDec '24Mar 2025: $897.8MMar '25Jun 2025: $1.05BJun '25Sep 2025: $1.13BSep '25Dec 2025: $1.20BDec '25Mar 2026: $1.07BMar '26Jun 2026: $1.21BJun '26Sep 2026: $1.24BSep '26Latest $1.24B
How JAZZ moved after its last 8 reports
Average move the session after a report ±5.6%
Oct 26, 2026After the close+0.5%
Aug 3, 2026After the close+4.0%
May 5, 2026After the close+7.7%
Feb 24, 2026After the close+13.2%
Jan 12, 2026Time not announced+1.6%
Nov 5, 2025After the close−2.3%
Aug 5, 2025After the close−6.4%
May 6, 2025After the close−8.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on JAZZStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on JAZZ
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on JAZZ

Technical Analysis

JAZZ · as of the Nov 20 close · updated each morning
Uptrend

The stock is 0% above its 20 day and 1% above its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 49). The nearest support is the 20 day average at $229.82, and the nearest resistance the Pivot at $232.27.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 3.5%/day
Key levels
$266.3852 week high+15.7%
$239.02100 day average+3.8%
$238.87Swing high (Oct 5)+3.7%
$236.58Pivot R1+2.7%
$232.27Pivot+0.9%
$230.26Last close
$229.8220 day average−0.2%
$229.16Swing low (Sep 29)−0.5%
$228.7450 day average−0.7%
$225.94Pivot S1−1.9%
$221.86200 day average−3.6%
$156.9552 week low−31.8%
Indicators
RSI (14)48.75Middle of its rangeNeutral
MACD4.40Above its signal lineBullish
Stochastic64.8Middle of its rangeNeutral
ADX (14)27.4Trending down
Williams %R-62.7Oversold below −80, overbought above −20Neutral
CCI (20)13.8Oversold below −100, overbought above 100Neutral
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$8.10Typical daily range, 3.5% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for JAZZ

What happened before

See how JAZZ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow JAZZ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How JAZZ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for JAZZHow many large options trades hit JAZZ, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

JAZZ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲367 buying vs 280 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +23
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding672649+3.5%
In funds' top 101114−21.4%
Held by funds102.4%100.3%+2.0 pts
New / increased104 / 263128 / 244−1.3%
Reduced / sold out204 / 76185 / 57+15.7%
Put/call ratio0.111.07−90.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JAZZ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

JAZZ Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$81.5M31 sales · 11 insiders
41% of the selling was under pre-arranged trading plans.
2025-12 sold $1.2M2026-02 sold $12.8M2026-03 sold $1.4M2026-04 sold $1.1M2026-05 sold $4.3M2026-06 sold $2.0M2026-07 sold $1.4M2026-08 sold $20.7M2026-09 sold $2.3M2026-10 sold $1.9M2026-11 sold $18.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 6Bruce C CozaddDirectorSale68,808$235.95$16.2M
Nov 4Patricia CarrSVP, Chief Accounting OfficerSale1,413$231.36$327K
Nov 3Renee D GalaPresident & CEOSale plan1,000$225.37$225K
Nov 2Bruce C CozaddDirectorSale plan6,000$215.84$1.3M
Oct 6Renee D GalaPresident & CEOSale plan2,000$236.40$473K
Oct 1Bruce C CozaddDirectorSale plan6,000$230.33$1.4M
Every insider buy and sale for JAZZ over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See JAZZ insider trades →

From SEC Form 4 filings by JAZZ's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JAZZ is in one of them and how their past JAZZ trades turned out.

JAZZ in the AI portfolios
Loading…

JAZZ News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JAZZ in an article yet. Here's the latest on the wider market.

JAZZ in the news

JAZZ Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 13
Who traded JAZZ · since 2015
Latest 5 filings of 7
$15K – $50KTraded Jul 12, 2023Filed Aug 13, 2023
$15K – $50KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Jan 31, 2023Filed Feb 24, 2023
$1K – $15KTraded Oct 19, 2021Filed Nov 5, 2021
$15K – $50KTraded Jul 15, 2019Filed Aug 12, 2019
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$15K – $50KJul 12, 2023Aug 13, 202332 d
Dan GoldmanD · NYBuy$15K – $50KMar 6, 2023Apr 17, 202342 d
Dan GoldmanD · NYSell$1K – $15KJan 31, 2023Feb 24, 202324 d
Tom SuozziD · NYBuy$1K – $15KOct 19, 2021Nov 5, 202117 d
Bill FloresR · TXBuy$15K – $50KJul 15, 2019Aug 12, 201928 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a biopharmaceutical company based in Dublin, Ireland. It develops and sells medicines for rare diseases, many of which have few or no existing treatment options. Its products include treatments for narcolepsy and other sleep disorders, medicines for certain forms of epilepsy, and cancer therapies. Its medicines are used by patients and prescribed by physicians in countries around the world.

Headquarters
Dublin
Founded
2003